相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)
Babafemi Taiwo et al.
AIDS (2011)
Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1
Eric S. Daar et al.
ANNALS OF INTERNAL MEDICINE (2011)
Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial
Calvin J. Cohen et al.
LANCET (2011)
The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters
Esteban Martinez et al.
AIDS (2010)
Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1-Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study
Jean-Michel Molina et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1-Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses
Jeffrey L. Lennox et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2010)
Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis
Anthony M. Mills et al.
AIDS (2009)
High Rate of Virologic Suppression with Raltegravir plus Etravirine and Darunavir/Ritonavir among Treatment-Experienced Patients Infected with Multidrug-Resistant HIV: Results of the ANRS 139 TRIO Trial
Y. Yazdanpanah et al.
CLINICAL INFECTIOUS DISEASES (2009)
The Forum for Collaborative HIV Research: A Model for an Integrated and Inclusive Approach to Clinical Research and Drug Development
V. Miller
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
HIV clinical trial design for antiretroviral development: moving forward
Kirk M. Chan-Tack et al.
AIDS (2008)
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection
David A. Cooper et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Class-sparing regimens for initial treatment of HIV-1 infection
Sharon A. Riddler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Maraviroc for previously treated patients with R5 HIV-1 infection
Roy M. Gulick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Raltegravir with optimized background therapy for resistant HIV-1 infection
Roy T. Steigbigel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Metabolic and Immune Activation Effects of Treatment Interruption in Chronic HIV-1 Infection: Implications for Cardiovascular Risk
Pablo Tebas et al.
PLOS ONE (2008)
Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study
Andrew N. Phillips et al.
LANCET (2007)
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial
Adriano Lazzarin et al.
LANCET (2007)
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial
Jose Valdez Madruga et al.
LANCET (2007)
Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN:: a randomised controlled phase III trial
Jose Valdez Madruga et al.
LANCET (2007)
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2:: a pooled subgroup analysis of data from two randomised trials
Bonaventura Clotet et al.
LANCET (2007)
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV
JE Gallant et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Antiretroviral therapies for treatment-experienced patients: current status and research challenges
K Struble et al.
AIDS (2005)
Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study
RT Schooley et al.
AIDS (2002)
分享论文
